Peptide conjugated particles

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely immunology and can be used for treating immunological disturbances. According to the invention tolerogenic composition comprises polystyrene carrier particle, carboxylated polysterene carrier particle, carrier particle of lactic and glycolic acids copolymer or a carboxylated carrier particle of lactic and glycolic acids copolymer, wherein this particle has a negative zeta potential and contains an encapsulated antigen. According to the invention the method comprises administering to the subject an effective amount of a tolerogenic composition.

EFFECT: use of inventions allows strengthening the antigen-specific tolerance in a subject by its stimulation with negatively charged particles of the lactic and glycolic acids copolymer.

25 cl, 39 dwg, 1 tbl, 22 ex



Same patents:

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds providing the targeted drug delivery to CD1d receptor cells and inducing an immune response as compared to an antigen, to based compositions and to a method using them applicable in medicine, of formula


wherein R1, R2, R3, and R4 represents hydrogen; R6 represents -(CH2)xCH3, x represents an integer from 20 to 25, or -(CH2)xCH=CH(CH2)yCH3, x, y and z independently represent an integer from 1 to 14, R5 is described by formula


wherein R8 represents hydrogen, R7 represents C3-C15 alkyl; X represents N; X represents -(CH2)t, wherein t is an integer within 3-10; Z represents a peptide antigen.

EFFECT: prepared are the new biologically active compounds effective for simulating the immune response.

12 cl, 6 dwg, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to the field of biotechnology, namely to the application of a conjugate of an immunogenic peptide and can be used in medicine. The said conjugate, containing 1÷93 of immunogenic peptides Aβ(35-42) (SEQ ID NO: 2), or 1÷93 of immunogenic peptides Aβ(33-42) (SEQ ID NO: 3), or 1÷93 of immunogenic peptides Aβ(33-40) (SEQ ID NO: 4), connected with a native albumin by means of a linker region, containing cysteine and a bifunctional linker, on condition that the linker region is connected by means of cysteine to the N-end of not more than one immunogenic peptide, can be used for the application in treatment or prevention of a disease, associated with the deposit of amyloid proteins. The invention also relates to the application of a pharmaceutical composition, containing the said conjugate, for the treatment or prevention of the disease, associated with the deposit of the amyloid proteins.

EFFECT: invention makes it possible to efficiently reduce levels of the amyloid peptide with the application of a simple in obtaining structure of the immunogenic peptide conjugate.

9 cl, 8 dwg, 7 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: what is presented is a fused protein that is a Notch1 antagonist, which consists of a human Fc region fused with the EGF-like repeat 1-13 of Notch1 or the EGF-like repeat 1-24 of Notch1. Fc-portion is localised on a carboxy-terminal portion of the EGF-repeat. There are described a pharmaceutical composition for the protein-based Notch signal transmission inhibition and using it for preparing the pharmaceutical composition for treating an individual suffering from: tumour; ovarian cancer; metabolic disorder; vascular proliferative retinopathy. What is presented is using the fused protein for producing the pharmaceutical composition for inhibition: angiogenesis in the individual; physiological lymphangiogenesis or pathological lymphangiogenesis in the individual; tumour deposits in the individual.

EFFECT: using the invention provides the proteins expressed in a supernatant at a level by several times more than the fused protein containing the EGF-like repeats 1-36 of Notch1; they penetrate into the tumour better, maintain a ligand-binding ability with the fused protein containing the repeats 1-24, binds to DLL4 and JAG1, whereas the fused protein containing the repeats 1-13 only binds to DLL4, but not to JAG1 that can find application in therapy of various diseases related to the Notch1 activity.

18 cl, 124 dwg, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to field of immunology and deals with polysaccharide-protein conjugate, composition, containing such conjugate, method of inducing immune response against Staphylococcus aureus in subject, methods of obtaining such conjugate and method of reducing or prevention of Staphylococcus aureus infection. Characterised conjugate contains capsular Staphylococcus aureus. Said conjugate contains capsular polysaccharide, conjugated with protein carrier Said polysaccharide represents polysaccharide of serotype 5 or serotype 8, has molecular weight between 70 kDa and 800 kDa and degree of O-acetylation between 75 and 100%. Methods of obtaining charactersed comjugate include covalent conjugation of capsular polysaccharides with protein carrier by chemical method with application of either 1,1-carbonyl-di-1,2,4-triazole (CDT) or 3-(2-pyridylthio)propionylhydraside (PDPH).

EFFECT: claimed solutions make it possible to obtain vaccine preparations against infections caused by Staphylococcus aureus with higher immunogenicity.

29 cl, 11 dwg, 25 tbl, 20 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to immunology, and can be used for treating drug abuse, industrial and domestic poisonings, and in man-induced disasters, etc. The invention represents a synthetic immunogen for the protection against toxic action of narcotic and psychoactive substances. The immunogen is presented in the form of a conjugate of a macromolecular carrier specified in: natural or artificial protein, oligo- and polypeptide, carbohydrate, lipid or nucleotide, and haptene - a narcotic or psychotropic compound, and additionally contains poly(4-nitrophenyl)acrylate covalently bond to the conjugate within the range of ratios 2 to 7 moles of the conjugate per one mole of poly(4-nitrophenyl)acrylate with the ratio of haptene and the macromolecular carrier in the conjugate makes 2-17 moles of haptene per 1 mole of the carrier.

EFFECT: using this invention leads to eliciting a stable immune response for a long period of time and providing the body protection against toxic action of the narcotic and psychotropic substances by produced specific haptene antibodies.

3 cl, 4 tbl, 29 ex

FIELD: chemistry.

SUBSTANCE: invention discloses an injection drug in form of a water-oil suspension of a chimeric protein with water-insoluble enzymatically inactive chloramphenicol acetyltransferase without 10 C-terminal amino acids, amino acid spacer (Sp)n, where n=1, 2, 4, 8, and a somatostatin-14 amino acid sequence AGCFWKTFTSC in refined vegetable oil with addition of apyrogenic water for injection. The invention also relates to a method of increasing human sperm production, which comprises hypodermic injection of said drug twice with an interval of 14-18 days in amount of 50-100 mcg protein per kg body weight.

EFFECT: invention improves reproductive capacity of men by increasing ejaculate volume, sperm count, the percentage of live, active sperm when the injection drug is used with low reactogenicity of the adjuvant, which allows painless injection.

6 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to field of biotechnology, in particular to immunogens based on antigenic tau-peptide, and can be used in medicine. Obtained is immunogen, which contains antigenic tau-peptide, consisting of amino acid sequence, selected from SEQ ID NO:6, 8-19, 21-26, 105 and 108-112, covalently bound with immunogenic carrier by means of linker, represented by formula (G)nC, where n equals 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Linker can be located either on C-terminal (peptide -(G)nC), or on N-terminal (C(G)n-peptide) of peptide. Obtained immunogens are used as base for creation of pharmaceutical compositions for treatment of tau-associated neurological disorders.

EFFECT: invention makes it possible to induce immune response against tau autoantigen in efficient way.

12 cl, 10 dwg, 5 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention discloses an immunogenic composition having an immunogenic activity on serogroup B and C Neisseria meningitidis containing (a) N. meningitidis serogroup C (NmC) oligosaccharide, (b) proteoliposome vesicles of the outer membrane of N.meningitidis (NmB) serogroup B and (c) NmB protein containing and an amino acid sequence presented in the description, or an immunogenic fragment of the above sequence, or a sequence min. 80% identical to the above sequence. The ingredient (a) may be conjugated with a carrier, e.g. with a protein, CRM197, a diphtherial anatoxin or a tetanus anatoxin. The immunogenic composition can contain aluminium hydroxide or MF59 as an adjuvant. What is described is a N.meningitidis serogroup B and C vaccine containing the described immunogenic composition.

EFFECT: using the invention enables preparing the combined vaccine eliciting an immune response on both serogroups of the agent.

6 cl, 4 dwg, 5 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology, more specifically, to using a chimeric somatostatin-containing protein for improving the reproductive properties of male farm animals and cocks, and may be used in veterinary science. The injection preparation is used in the form of a chimeric protein suspension with water-insoluble enzyme-inactive chloramphenicol acetyltransferase with no 10 C-terminal amino acids, amino acid spacer (Sp)n, wherein n=1, 2, 4, 8 and somatostatin-14 with AGCFWKTFTSC amino acid sequence in the refined vegetable oil with bee wax added at 250-1000 mg of the above chimeric protein per 100 ml of the refined vegetable oil containing 0.9-1.1 wt % of bee wax. The injection preparation is used in cocks and farm animals after achieving the physiological maturity at 50-200 mcg of the protein per 1 kg of a live body weight.

EFFECT: invention enables increasing sperm production: increasing the ejaculate volume and reducing the biologically damaged sperm in farm animals and cocks by using the preparation for injections with a low-reactogenicity adjuvant.

2 cl, 13 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a composition for nicotinic immunonanotherapy containing synthetic nanocarriers having a polymeric surface conjugated with a variety of nicotine residues with the variety of the nicotinic residues on the nanocarrier form an immunogenic surface providing a low affinity, a high-avidity binding of the nicotinic residues to the surfaces of an antigen presenting cell (APC) compared with an antibody binding, and a pharmaceutically acceptable excipient. The invention provides the nanocarriers capable to stimulate an immune response in T-cells and/or B cells and to produce the antinicotin antibodies with the humoral and cellular response to be achieved in the absence of an exogenous adjuvant.

EFFECT: invention provides the absence of the non-specific response on an inflammation caused by an adjuvant.

17 cl, 37 dwg

FIELD: immunology.

SUBSTANCE: the innovation deals with new immunogenic conjugates of beta-propionamide-bound polysaccharide and N-propionamide-bound oligosaccharide with protein, and the method to obtain these conjugates has been suggested, as well. Conjugates should be applied to obtain vaccines against infectious diseases and cancer that enables to broaden the number of preparations applied in treating the above-mentioned diseases.

EFFECT: higher efficiency.

1 dwg, 2 ex, 8 tbl